There are 2789 resources available
278P - Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Presenter: Sergei Krasny
Session: ePoster Display
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
281P - Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Presenter: Gaia Griguolo
Session: ePoster Display
282P - Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Presenter: Abirami Sivapiragasam
Session: ePoster Display
200TiP - ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor (HER2) positive, early breast cancer (eBC) observing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO
Presenter: Nadia Harbeck
Session: ePoster Display
201TiP - Evaluation of the feasibility of ultrasound-guided clipping of suspicious intramammary lesions in primary breast cancer patients receiving neoadjuvant therapy (Ultra3Detect)
Presenter: Efstathia Vlachou
Session: ePoster Display
203P - Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer
Presenter: Marina Cazzaniga
Session: ePoster Display
204P - Predictive factors for relapse in triple-negative breast cancer (TNBC) patients without pathologic complete response (PCR)
Presenter: Marta Venturelli
Session: ePoster Display